Saturday, 27 April 2024
Bellerophon Therapeutics Llc
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases.
more»
14:30 | 23/2/18
Frisco Fastball
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases.
more»
09:58 | 22/2/18
Collins Courier
Bargain stock hunters have honed in their attention of late on shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH).
more»
07:16 | 10/2/18
FLBC News
There are many different tools to determine whether a company is profitable or not. One of the most popular ratios is the “Return on Assets” (aka ROA).
more»
published on April 10, 2017, Marketwatch.com published: “Bellerophon Therapeutics Inc.” on April 06, 2017. More interesting news about Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) were released by: Globenewswire.com and their article: “Bellerophon ...
more»
18:15 | 4/2/18
Stock Talker
The Value Composite 2 (VC2) is a ranking system that is calculated by using the price to book value, price to sales, EBITDA to EV, price to cash flow, price to earnings and shareholder yield.
more»
02:30 | 30/1/18
GlobeNewswire
WARREN, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that enrollment in its Phase 3 INOvation-1 study evaluating INOpulse® in patients with pulmonary ...
more»
01:00 | 30/1/18
The Lincolnian Online
Bellerophon Therapeutics earned a coverage optimism score of 0.15 on Accern's scale. Accern also gave news articles about the biotechnology company an impact score of 44.8259439887245 out of 100, meaning that recent media coverage is somewhat unlikely ...
more»
The chart of Bellerophon Therapeutics, Inc. (BLPH) shows a double top with $2.63 target or 9.00 % above today's $2.41 share price.
more»
04:00 | 20/1/18
The Ledger Gazette
Bellerophon Therapeutics logo Media stories about Bellerophon Therapeutics (NASDAQ:BLPH) have trended somewhat positive this week, Accern Sentiment Analysis reports.
more»
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |